Sio Gene Therapies to Participate in Upcoming Investor & Scientific Conferences

Rhea-AI Summary

Sio Gene Therapies Inc. (NASDAQ: SIOX), focused on gene therapies for neurodegenerative diseases, will participate in several upcoming investor and scientific conferences.

• Oppenheimer Conference: Presentation on March 17, 2021, at 2:30 PM ET by Gavin Corcoran.
• Redburn Gene Therapy Summit: Panel discussion on March 31, 2021, at 8:00 AM ET led by Parag V. Meswani.
• Guggenheim Healthcare Talks: 1-on-1 investor meetings on April 1, 2021.
• Gene Therapy Patient Engagement Summit: March 23-25, 2021.

The company aims to radically improve lives through innovative genetic medicines.

NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences. Details can be found below.

Oppenheimer 31st Annual Healthcare Conference
Participation:	Company presentation and 1-on-1 investor meetings
Presenter:	Gavin Corcoran, MD, Chief R&D Officer
Presentation Date & Time:	Wednesday, March 17, 2021 at 2:30 PM ET
Webcast:	https://wsw.com/webcast/oppenheimer9/siox/2762815
Redburn Gene Therapy Virtual Summit
Participation:	Panel discussion: “Defining a Gene Therapy Market”
Presenter:	Parag V. Meswani, PharmD, Chief Commercial Officer
Panel Date & Time:	Wednesday, March 31, 2021 at 8:00 AM ET
Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease Day
Participation:	1-on-1 investor meetings
Date:	Thursday, April 1, 2021
Gene Therapy Patient Engagement Summit
Date:	March 23-25, 2021

About Sio Gene Therapies

Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit www.siogtx.com.

Contacts:

Media

Josephine Belluardo, Ph.D.
LifeSci Communications
(646) 751-4361
jo@lifescicomms.com
info@siogtx.com

Investors and Analysts

Parag V. Meswani
Sio Gene Therapies Inc.
Chief Commercial Officer
investors@siogtx.com

FAQ

What is Sio Gene Therapies' participation in the Oppenheimer Conference?

Sio Gene Therapies will present at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 2:30 PM ET.

Who is presenting at the Redburn Gene Therapy Virtual Summit?

Parag V. Meswani, the Chief Commercial Officer, will lead a panel discussion on March 31, 2021.

When are the Guggenheim Healthcare Talks scheduled?

Sio Gene Therapies will hold 1-on-1 investor meetings on April 1, 2021, during the Guggenheim Healthcare Talks.

What dates is the Gene Therapy Patient Engagement Summit taking place?

The Gene Therapy Patient Engagement Summit is scheduled for March 23-25, 2021.